SLC5A5 and head and neck squamous cell carcinoma: A phase I trial (NCT01846091), currently underway, is designed to evaluate the safety and immunological effects of MV-NIS (an oncolytic measles virus encoding thyroidal sodium iodide symporter) in R/M HNSCC.